[1]Tsibiribi P., Descotes J., Lombard-Bohas C. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer (Paris). 2006;93:E27-30.
[2]Tajik R, Saadat H, Taherkhani M, Movahed MR. Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. Am Heart Hosp J 2010 ; 8 : E111-112.
[3]Camaro C., Danse P.W., Bosker H.A. Acute chest pain in a patient treated with capecitabine. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2009;17:288-291.
[4]Luwaert R.J., Descamps O., Majois F., Chaudron J.M., Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991;12:468-470.
[5]Südhoff T., Enderle M.-D., Pahlke M., Petz C., Teschendorf C., Graeven U., Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661-664.
[6]Cwikiel M., Zhang B., Eskilsson J., Wieslander J.B., Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995;9:561-576.
[7]Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine : more than just vasospastic angina. Intern Med J 2010 ; 40 : 303-307.
[8]De Forni M., Malet-Martino M.C., Jaillais P. Cardiotoxicity of high-dose continuous infusion fluorouracil : a prospective clinical study. J Clin Oncol. 1992;10:1795-1801.
[9]Mosseri M., Fingert H.J., Varticovski L., Chokshi S., Isner J.M. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028-3033.
[10]Schalkwijk CG, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction : evidence for chronic inflammation. Diabetologia 1999 ; 42 : 351-357.
[11]Millart H., Brabant L., Lorenzato M., Lamiable D., Albert O., Choisy H. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res. 1992;12:571-576.
[12]Tamatsu H., Nakazawa M., Imai S., Watari H. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5’-deoxy-5-fluorouridine (5’-DFUR). Jpn J Pharmacol. 1984;34:375-379.
[13]Durak I., Karaayvaz M., Kavutcu M. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A. 2000;59:585-589.
[14]Matsubara I., Kamiya J., Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol. 1980;30:871-879.
[15]Becker K., Erckenbrecht J.F., Häussinger D., Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57:475-484.
[16]Grunwald M.R., Howie L., Diaz L.A. Takotsubo cardiomyopathy and Fluorouracil: Case report and review of the literature. J Clin Oncol. 2012;30:e11-14.
[17]Guo X.-D., Harold N., Saif M.W. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol. 2003;52:79-85.
[18]Arellano M., Malet-Martino M., Martino R., Gires P. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer. 1998;77:79-86.
[19]Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
[20]Polk A, Shahmarvand N, Vistisen K, et al. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: A retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open 2016 ; 6 : e012798.
[21]Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014 ; 15 : 47.
[22]Polk A., Vaage-Nilsen M., Vistisen K., Nielsen D.L. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974-984.
[23]Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: Challenging the current paradigm. J Gastrointest Oncol 2017 ; 8 : 970-979.
[24]Sara J.D., Kaur J., Khodadadi R. 5-fluorouracil and cardiotoxicity: A review. Ther Adv Med Oncol. 2018;10:1758835918780140.
[25]Saif M.W., Shah M.M., Shah A.R. Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opin Drug Saf. 2009;8:191-202.
[26]Eskilsson J., Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol Stockh Swed. 1990;29:1001-1003.
[27]Ambrosy A.P., Kunz P.L., Fisher G.A., Witteles R.M. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110:1623-1626.
[28]Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006 ; 58 : 487-493.
[29]Bakouboula B, Morel O, Douchet MP, Chauvin M. Reversible cardiogenic shock under 5-fluorouracil treatment. Ann Cardiol Angeiol (Paris) 2005 ; 54 : 216-219.
[30]Saif M.W., Garcon M.C., Rodriguez G., Rodriguez T. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: A case series. Vivo Athens Greece. 2013;27:531-534.
[31]Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003 ; 88 : 1507-1509.